Gastroparesis
- Home
- Solutions
- By Diseases
- Gastric Diseases
- Gastroparesis
Gastroparesis can be described as a damaging disorder commonly linked with high rates of disability and mortality caused by a grave case of stomach emptying delay. Protheragen provides services to our clients regarding specialist preclinical gastroparesis drug development along with comprehensive support of needed preclinical research that will boost their research projects.
Gastroparesis is a syndrome defined by delayed gastric emptying without the presence of a mechanical obstruction. An epidemiological study showed the prevalence of gastroparesis is 24.2 per 100,000 population. The most common symptoms are early satiation, postprandial fullness, nausea-vomiting, abdominal bloating, and pain.
Fig.1 Risk factors for gastroparesis. (Egboh, S. C., and Abere, S., 2022)
Multiple factors are responsible for the underlying mechanisms of impaired gastric emptying in individuals suffering from gastroparesis. These include extrinsic denervation to the stomach, lack of inhibitory input to smooth muscles as a result of decreased nitric oxide in the enteric nervous system, loss of interstitial cells of Cajal (ICC, which serve as pacemakers), atrophied smooth muscles, and altered immune cell's function, among others. ICC works by producing electrical slow waves in the stomach; thus, impairments in the ICC network and gastric dysrhythmias have been linked with the development of gastroparesis.
Fig.2 Pathophysiologic mechanisms of gastroparesis. (Cangemi, D. J., and Lacy, B. E., 2023)| Drug Names | Mechanism of Action | Targets | Research Phase |
| Metoclopramide | Inhibition of D2 receptors and 5-HT3 receptors within the central nervous system. | Dopamine 2 receptor | Approved |
| Relamorelin | Enhancing gastric emptying by acting as a 5-HT4 agonist. | GHSR | Phase III |
| Velusetrag | Increases gastric emptying rate in individuals suffering from gastroparesis. | 5HT4 receptor | Phase II |
| Trazpiroben | It acts as a D2/D3 receptor antagonist to promote gastric emptying. | D2/D3 receptor | Phase II |
Disclaimer: Protheragen focuses on providing preclinical research services. This table is for information exchange purposes only. This table is not a treatment plan recommendation. For guidance on treatment options, please visit a regular hospital.
Protheragen focus on working closely and communicating efficiently with our clients to achieve positive results in drug development for gastrointestinal diseases like gastroparesis. From novel diagnostics and effective therapeutics to a range of disease model development, we are prepared to assist you in your efforts and propel the progress of gastroparesis research.
For understanding the pathophysiology of gastroparesis, therapies to be tested, and the development of related technologies, animal models are of great importance. We provide animal model development services on a custom basis and refine them according to changing research needs.
Integrating our experience in the preclinical stages of drug development with pharmacokinetic and biosafety testing, Protheragen offers a more complete approach to drug development by ensuring safety along with efficacy. Partner with us to leverage our comprehensive services and drive your drug development efforts toward success. Reach out to us and we can assist you with any questions regarding our extensive services.
References
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.